Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

293
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
293
Inflammatory Response01:28

Inflammatory Response

8.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
8.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

459
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
459
T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

671
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
671

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction and diagnosis of post-stroke epilepsy using artificial intelligence approaches: a systematic review and meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Optical Bistability in Photonic Topological Hypercrystals and Its Applications in Photonic Neural Network.

Nanomaterials (Basel, Switzerland)·2026
Same author

Microglial GPR35 Ameliorates Epileptogenesis and Neuroinflammation via PDGFA Domain 2 Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Chronic 40 Hz light flicker mitigates epileptogenesis through a visual pathway associated with the dorsal lateral geniculate nucleus shell.

Nature communications·2025
Same author

Glymphatic system dysfunction and its impact on seizure severity, cognitive function, and affective symptoms in patients with generalized tonic-clonic seizures alone.

Journal of the neurological sciences·2025
Same author

Nanoparticles modified with glucose analogs to enhance the permeability of the blood-brain barrier and their accumulation in the epileptic brain.

Journal of materials chemistry. B·2025
Same journal

Association Between Neutrophil Percentage-to-Albumin Ratio and All-Cause Mortality and Cardiovascular Events in Patients with Diabetic Foot Ulcers: A Retrospective Cohort Study.

Journal of inflammation research·2026
Same journal

R788 is Associated with Neuroprotective Effects in Experimental Ischemic Stroke Models via Modulation of the STAT1/Nrf2/GPX4 Axis.

Journal of inflammation research·2026
Same journal

Peripheral Blood Mononuclear Cells in Sepsis: Immune Trajectories, Monocyte Dysfunction, and Translational Biomarkers.

Journal of inflammation research·2026
Same journal

PD-1/TIGIT CD4⁺ T-Cell Signature for Risk Stratification of Post-Weaning Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients.

Journal of inflammation research·2026
Same journal

Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study.

Journal of inflammation research·2026
Same journal

Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study.

Journal of inflammation research·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K

Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation

Hanli Li1,2, Zhong Dong2, Yujing Yang3

  • 1School of Clinical Medicine, Anhui Medical College, Hefei, People's Republic of China.

Journal of Inflammation Research
|July 2, 2025
PubMed
Summary
This summary is machine-generated.

Specialized pro-resolving lipid mediators (SPMs) like Resolvin D1 (RvD1) and Resolvin E1 (RvE1) were decreased in chronic epilepsy patients. This suggests impaired inflammation resolution, highlighting potential therapeutic targets.

Keywords:
chronic epilepsyinflammationresolvin D1resolvin E1specialized pro-resolving lipid mediators

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Related Experiment Videos

Last Updated: Sep 17, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.2K

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Inflammation resolution is crucial for maintaining health.
  • Specialized pro-resolving lipid mediators (SPMs) are key players in this process.
  • Understanding SPM alterations in chronic neurological conditions like epilepsy is of significant interest.

Purpose of the Study:

  • To investigate the levels of SPMs in patients with chronic epilepsy.
  • To explore the relationship between SPM levels and epilepsy severity.
  • To determine if inflammation resolution pathways are impaired in chronic epilepsy.

Main Methods:

  • Collected plasma and cerebrospinal fluid (CSF) from 65 chronic epilepsy patients, 43 healthy controls, and 43 patients with non-inflammatory neurological disorders.
  • Quantified SPM levels using liquid chromatography-tandem mass spectrometry (LC-MS-MS).
  • Analyzed Resolvin D1 (RvD1) and Resolvin E1 (RvE1) using ELISA, alongside pro-inflammatory factors.

Main Results:

  • Significantly decreased plasma and CSF levels of RvE1 were observed in chronic epilepsy patients.
  • Both RvD1 and RvE1 levels were lower in plasma and CSF of epilepsy patients compared to controls.
  • Elevated pro-inflammatory factors were found in epilepsy patients, with RvE1 negatively associated with seizure severity and RvD1 correlated with cognitive scores.

Conclusions:

  • Chronic epilepsy is associated with reduced levels of RvD1 and RvE1 in both plasma and CSF.
  • These findings suggest an impairment in the resolution of inflammation in chronic epilepsy.
  • Targeting RvD1 and RvE1 presents a potential novel therapeutic strategy for chronic epilepsy.